Peer-influenced content. Sources you trust. No registration required. This is HCN.

Features:
CME JOBS OUTBREAKS PEER-TO-PEER QUIZZES & QUESTIONS MEDTECH

Journal of Clinical OncologyAtezolizumab with Neoadjuvant Anti–HER2 Therapy and Chemotherapy in HER2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial

The IMpassion050 study was the first to assess the question: Can addition of atezolizumab to neoadjuvant standard of care (pertuzumab and trastuzumab [PH], and chemotherapy) improve outcomes in high-risk, HER2–positive early breast cancer? The results are a click away.

Was this Essential useful?

More Essentials From

ACP Internist
Annals of Internal Medicine
British Medical Journal
Cancer Therapy Advisor
Cleveland Clinic Journal of Medicine
Clinical Advisor
Consultant360
Dana-Farber Cancer Institute
Healthgrades for Professionals
MDLinx
Neurology Advisor
OBR Oncology
Oncology Learning Network
Psych Congress Network
Psychiatrist.com
The Epoch Times
The New England Journal of Medicine
The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form